Contineum CSO sells stock, exercises options

Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported paired option exercises and stock sales in Class A Common Stock.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported paired option exercises and stock sales in Class A Common Stock. He exercised options covering 1,040 shares at $1.01 per share and sold 1,040 shares at $16.00 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse.

Insights

Equity analyst

Contineum’s CSO exercised options and sold an equal number of shares under a pre-set plan.

Chief Scientific Officer Daniel S. Lorrain exercised stock options for 1,040 shares of Class A Common Stock at an exercise price of $1.01 per share, then sold the same number of shares at $16.00 per share in open-market transactions. This pattern is typical of option exercise-and-sell activity, converting previously granted equity compensation into cash.

The filing notes these trades were effected under a Rule 10b5-1 trading plan adopted on September 23, 2025, indicating they were pre-scheduled rather than discretionary market timing. After the transactions, Lorrain continues to hold 135,202 shares directly and 10,110 shares indirectly through his spouse, maintaining a meaningful equity stake aligned with shareholders.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,040 shares ($16K approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 1,040 shs ($17K)

Approx. gross sale proceeds $17K

Approx. exercise cost $1K

Approx. pre-tax spread $16K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F2	25	$0.00	$0.00
Exercise	Class A Common Stock F1	25	$1.01	$25.25
Sale	Class A Common Stock F1	25	$16.00	$400.00
Exercise	Stock Option (right to buy) F1, F2	1,015	$0.00	$0.00
Exercise	Class A Common Stock F1	1,015	$1.01	$1K
Sale	Class A Common Stock F1	1,015	$16.00	$16K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 33,257 contracts (Direct); Class A Common Stock — 135,202 shares (Direct); Class A Common Stock — 10,110 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. The stock options are fully vested and exercisable.

Key Figures

Shares sold: 1,040 shares Sale price per share: $16.00 Option exercise price: $1.01 +3 more

6 metrics

Shares sold 1,040 shares Total Class A Common Stock sold in open-market transactions

Sale price per share $16.00 Price for Class A Common Stock open-market sales

Option exercise price $1.01 Exercise price for stock options converted into Class A Common Stock

Direct holdings after transactions 135,202 shares Class A Common Stock held directly by Daniel S. Lorrain after reported trades

Indirect holdings by spouse 10,110 shares Class A Common Stock held indirectly through spouse

Shares exercised 1,040 shares Total underlying shares acquired via option exercises

Key Terms

Rule 10b5-1 trading plan, open-market sale, Stock Option (right to buy), fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

fully vested and exercisable financial

"The stock options are fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CTNM Chief Scientific Officer Daniel S. Lorrain report?

Daniel S. Lorrain reported exercising stock options for 1,040 shares of Contineum Therapeutics Class A Common Stock at $1.01 per share and selling 1,040 shares in open-market transactions at $16.00 per share.

How many Contineum Therapeutics (CTNM) shares did the CSO sell and at what price?

Daniel S. Lorrain sold a total of 1,040 shares of Contineum Therapeutics Class A Common Stock at an open-market sale price of $16.00 per share, according to the Form 4 filing.

At what price were the Contineum Therapeutics (CTNM) stock options exercised by the CSO?

The reported stock options were exercised for 1,040 shares of Contineum Therapeutics Class A Common Stock at an exercise price of $1.01 per share, reflecting previously granted compensation options that were fully vested and exercisable.

How many CTNM shares does the Contineum Therapeutics CSO hold after these transactions?

After the reported transactions, Daniel S. Lorrain holds 135,202 shares directly of Contineum Therapeutics Class A Common Stock and 10,110 shares indirectly through his spouse, as disclosed in the Form 4.

Were the recent CTNM insider transactions by the CSO under a Rule 10b5-1 plan?

Yes. The Form 4 states that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Daniel S. Lorrain on September 23, 2025, indicating they were pre-arranged.

What derivative securities were involved in the Contineum Therapeutics (CTNM) CSO Form 4?

The filing shows exercises of stock options (rights to buy) for 1,040 underlying shares of Contineum Therapeutics Class A Common Stock at a $1.01 conversion price, with the options described as fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/08/2026		M(1)		1,015	A	$1.01	136,217	D
Class A Common Stock	07/08/2026		S(1)		1,015	D	$16	135,202	D
Class A Common Stock	07/09/2026		M(1)		25	A	$1.01	135,227	D
Class A Common Stock	07/09/2026		S(1)		25	D	$16	135,202	D
Class A Common Stock								10,110	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	07/08/2026		M(1)			1,015	(2)	02/24/2030	Class A Common Stock	1,015	$0	33,282	D
Stock Option (right to buy)	$1.01	07/09/2026		M(1)			25	(2)	02/24/2030	Class A Common Stock	25	$0	33,257	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The stock options are fully vested and exercisable.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)